Our results indicated that the inhibition of HDAC and simultaneous activation of RXR increases the expression of HtrA1, thus increasing the response of CDDP-resistant NSCLC cells to cisplatin and inhibiting the migration and invasion of CDDP-resistant cells. The gene discussed is HTRA1; the disease is non-small cell lung carcinoma.